#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis

Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.
Source: Modern Treatment of Schizophrenia 1. 11. 2022

News Does the type of oral anticoagulant affect heparin dosing during catheter ablation?

During catheter ablation, which patients undergo as part of atrial fibrillation (AF) treatment, current guidelines recommend the administration of heparin without interrupting oral anticoagulant therapy. A recently published analysis evaluated whether the type of oral anticoagulant affects the total dose of heparin administered during the ablation.
Source: Anticoagulant Treatment 22. 3. 2021

News Collagen Turnover as a Biomarker of Hemophilia Treatment Efficacy

Over the past decades, hemophilia treatment has made significant progress—from factor therapy to prophylactic regimens and non-factor products, and even to gene therapy. Its development has greatly improved the quality of life for hemophiliacs and reduced the incidence of bleeding episodes. However, they cannot be completely eliminated, which is why further options for monitoring bleeding and joint status are still being explored. In addition to classical methods, biomarkers are attracting attention, but their practical use is still the subject of studies. A recently published work by a team of European and American experts, who assessed collagen turnover as a biomarker of treatment efficacy with rurioctocog alfa pegol, came with interesting results.
Source: Hemophilia 10. 6. 2024

News Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines

Two leading overseas medical professional societies, the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), released new recommendations for diabetes treatment in December 2016. They include information on the reduction of cardiovascular mortality in diabetics treated with empagliflozin (Jardiance).
Source: Diabetes 14. 2. 2020

News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy

Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.
Source: Epilepsy 8. 6. 2023

News Comparison of BEAM and TEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Lymphomas

At the beginning of this year, one of the few studies comparing the most commonly used conditioning regimen before autologous hematopoietic stem cell transplantation (ASCT) in patients with lymphomas (BEAM) with a regimen containing thiotepa instead of carmustine (TEAM) was published.
Source: Oncological Treatment 13. 6. 2023

News Safety of Metamizole in Adult Patients – Meta-analysis of 79 Studies

Metamizole is a non-opioid analgesic with antipyretic and spasmolytic effects that has been used for over 100 years. It is approved for the treatment of children and adults in various dosage forms. German authors conducted a systematic literature review and meta-analysis of clinical studies to evaluate its safety compared to placebo and other analgesics in adult patients.
Source: Analgesia 30. 5. 2024

News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics

Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.
Source: Deficiency of Alpha-1-Antitrypsin 14. 5. 2021

News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency

Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.
Source: Deficiency of Alpha-1-Antitrypsin 12. 1. 2022

News Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results

Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the treatment of ulcerative colitis (UC) in adult patients. We summarize the results of the phase III placebo-controlled True North study published in the New England Journal of Medicine, which demonstrated efficacy and safety in both induction and maintenance therapy for UC.
Source: Modulation of S1P in the Treatment of Autoimmune Diseases 9. 5. 2023

News Does adding statins to DOACs reduce the risk of major bleeding in patients with non-valvular atrial fibrillation?

A large retrospective study, the results of which were recently published, investigated to what extent the concurrent administration of statins is associated with a lower risk of major bleeding, including intracranial and gastrointestinal bleeding, in patients with non-valvular atrial fibrillation taking direct oral anticoagulants (DOACs).
Source: Anticoagulant Treatment 1. 11. 2022

News Mental Health as an Overlooked Topic in Patients with Psoriasis

Psoriasis is an inflammatory, non-infectious disease primarily affecting the skin, and sometimes the nails, although in some patients, it manifests as psoriatic arthritis. To minimize the negative impact of these stigmatizing issues on patients' daily lives, not only optimal pharmacotherapy is crucial, but also the support of mental health.
Source: Psoriasis 4. 7. 2023

News Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP

Recommendations for the care of acute, especially major bleeding in individuals with severe immune thrombocytopenia (ITP) are not entirely clear. Various methods (steroid boluses, intravenous immunoglobulins, platelet transfusions, etc.) can be used to quickly increase platelet count, but the response may not always be straightforward. Recently, reports have been published regarding the use of thrombopoietin receptor agonists (TPO-RAs) specifically aimed at rapidly increasing platelet count. The use of romiplostim in patients with ITP and intracranial hemorrhage is illustrated by the following case studies.
Source: Immune Thrombocytopenia 10. 8. 2022

News Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade – Case Report

Painful and potentially life-threatening swellings are characteristic of hereditary angioedema (HAE), a rare genetically determined disease. Dutch authors present in a recently published review the case report of a young woman with a life-threatening laryngeal swelling.
Source: Hereditary Angioedema 25. 8. 2023

News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure

Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.
Source: Intestinal Inflammations 21. 8. 2022

News Comparison of Three Thromboprophylactic Regimens in Patients Post Pancreatic Surgery

Post-pancreatectomy bleeding and thromboembolic disease are among the serious complications of pancreatic surgeries. The aim of the study published last year in the British Journal of Surgery was to compare the efficacy and safety of different dosing regimens of low-molecular-weight heparin nadroparin in patients undergoing oncologic pancreatic surgery.
Source: Prevention of Thrombosis in Surgery 18. 5. 2020

News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes

The proven benefit of one class of antidiabetic drugs – sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) – in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.
Source: Cardiovascular Continuum 18. 11. 2021

News Emicizumab Changes the Lifestyle of Patients with Hemophilia A

At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.
Source: Quality Life Even with Hemophilia 30. 9. 2020

Journal articles Anaesthesia for minor surgery in the early postpartum period – Czech and Slovak prospective national surveys

Author of the article: P. Tourač, J. Bláha, P. Nosková, R. Klozová, D. Seidlová, M. Grochová, M. Kosinová, J. Jarkovský, H. Zelinková, D. Schwarz, M. Svoboda, S. Richterová, O. Smékalová, B. Zaoralová, Z. Mrozek, Z. Krupková, L. Večeřa, H. Ivanková, A. Magyarová, J. Šimonová, J. Firment Source: Anesteziologie a intenzivní medicína | 2/2019 13. 5. 2019

News Is Obesity a Universal Phenotype in Children with Type 2 Diabetes?

What is the global prevalence of obesity in children and adolescents suffering from type 2 diabetes mellitus (T2DM)? Does the occurrence of obesity in pediatric T2DM correlate with gender or race? And how is obesity in T2DM under 18 years of age associated with glycemic control and dyslipidemia? These questions have been addressed by Canadian authors in their recently published systematic review and meta-analysis, which deals with various issues related to childhood obesity.
Source: Modern Treatment of Diabetes 19. 4. 2023

News Interactive Case Study: Treatment of Neuropathic Pain in a Patient with Neurodegenerative Disease

We offer a brief case study of a polymorbid patient suffering from chronic pain, spasticity, and sleep disturbances, among other issues. Medical cannabis was advantageously introduced, helping to alleviate several symptoms. You can interactively explore how you would proceed in this case.
Source: Medical Cannabis 22. 4. 2024

News Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.
Source: Non-Hodgkin Lymphomas and CLL 27. 1. 2020

News Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type 2 diabetes mellitus (T2DM) and chronic heart failure regardless of ejection fraction value. Its impact on renal function and the prognosis of patients with chronic kidney disease (CKD) irrespective of the presence of T2DM was specifically evaluated in the double-blind placebo-controlled EMPA-KIDNEY study.
Source: Diabetes 18. 10. 2023

News Development of Albuminuria During Treatment with ACE Inhibitors and Sartans

Individual molecules from the class of renin-angiotensin system inhibitors display various distinct properties at the molecular level, and their renoprotective potential may differ. A study by Korean authors observed the development of renal parameters in individuals with albuminuria during the first 3 months after the initiation of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), also known as sartans.
Source: Sartans in the Treatment of Hypertension 25. 5. 2020

News Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?

Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the renin-angiotensin system possibly being the central mediator of the connection between these diseases. The German study cited below therefore examined whether therapy with AT1 receptor blockers for angiotensin II (ARBs, i.e., sartans) reduces the risk of epilepsy in patients with AH as suggested by animal studies.
Source: Sartans in the Treatment of Hypertension 25. 5. 2023

1 20 21 22 23 24 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#